Table 3 Trials of GLP-1RAs on HF outcomes
From: DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
Characteristic | LIVE (2016) [91] | FIGHT (2016) [90] |
|---|---|---|
Drug | Liraglutide | Liraglutide |
Comparative agent | Placebo | Placebo |
Follow-up period (weeks) | 24.0 | 25.7 |
Inclusion criteria | Patients aged 30–85 years with CHF; LVEF ≤ 45%; functional class I–III; patients both with and without T2DM were included | HF with LVEF ≤ 40%; hospitalization for acute HF within last 14 d despite prior treatment; preadmission dose of 40 mg of furosemide or equivalent |
Exclusion criteria | Class IV HF; MI within the last 3 months; type 1 diabetes; HbA1c > 10%; heart disease hospitalization in last 30 d; Afib with ventricular frequency above 100/min at rest; coronary revascularization within the last 3 months; obstructive hypertrophic cardiomyopathy; use of GLP-1RAs within last 30 d | Acute coronary syndrome or intervention; intolerance to GLP-1RAs; severe renal, hepatic, or pulmonary failure |
Primary endpoint | Change in LVEF | Global rank score (higher values indicated better health): time to death, time to rehospitalization for HF, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 d |
Results of endpoint | Absolute increase in LVEF: (0.8 ± 4.7)% vs. (1.7 ± 4.4)% [mean difference − 0.9% (95% CI − 2.1–0.3), P = 0.15] | Death: 12% vs. 11% (HR = 1.10, 95% CI 0.57–2.14; P = 0.78); rehospitalization for HF: 41% vs. 31% (HR = 1.30, 95% CI 0.89–1.88; P = 0.17); composite of death or rehospitalization for HF: 47% vs. 39% (HR = 1.30, 95% CI 0.92–1.83; P = 0.14) |